A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
"Spend less time on paperwork and more time on care. Upgrade your workflow with MTS’s medical transcription services that deliver fast, accurate records, keeping your team productive and patients happy.
#MedicalTranscription #WorkflowEfficiency #HealthcareOperations"
"Spend less time on paperwork and more time on care. Upgrade your workflow with MTS’s medical transcription services that deliver fast, accurate records, keeping your team productive and patients happy.
#MedicalTranscription #WorkflowEfficiency #HealthcareOperations"
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
In honor of World Pancreatic Cancer Day on Nov. 16, people around the world will come together to Demand Better in the fight against the world’s toughest cancer, starting with earlier diagnosis. The annual one-day campaign is an initiative of the World Pancreatic Cancer Coalition, which is comprised of more than 60 organizations from 27 countries on six continents.
Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer. Of that, an estimated 985 will die from the disease. Additionally, pancreatic cancer has the lowest survival rate among all major cancers, and in nearly every country, it is the only major cancer with a single-digit five-year survival rate (2-9 percent). These stunning figures are not merely statistics, they represent family members, friends and colleagues on every corner of the globe.
“This year, we are turning World Pancreatic Cancer Day from a day of awareness to a day of action,” said Julie Fleshman, JD, MBA, World Pancreatic Cancer Coalition chair. “As we expand our global movement to end pancreatic cancer, we are demanding better for pancreatic cancer patients now and in the future.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8201651-world-pancreatic-cancer-day-demand-better/
As millions of Americans begin choosing a health plan for the first time under the Affordable Care Act, the new Healthgrades American Hospital Quality Outcomes 2014: Report to the Nation released today reveals how hospital selection can dramatically impact a patient’s health. The report demonstrates that individuals are far more likely to die or suffer complications at hospitals receiving the lowest Healthgrades rating. In fact, each year an estimated 234,252 lives could potentially be saved and 157,418 complications could be avoided if all hospitals performed similarly to the highest rated hospitals.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63942-healthgrades-american-hospital-quality-outcomes-2014-report-to-the-nation
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Baylor University Medical Center at Dallas (Baylor Dallas) is now home to North Texas’ largest outpatient cancer center. The new Baylor Charles A. Sammons Cancer Center at Dallas opens to the public Saturday, March 26. The 467,000 square-foot facility marks a new era in cancer care for the Dallas-Fort Worth Metroplex and beyond by offering comprehensive services for cancer patients from initial diagnosis through post-recovery. Baylor Dallas, already the leading cancer care provider in North Texas in terms of patients treated and according to Consumer Choice data, now brings together multiple phases of cancer care under one roof.
To view Multimedia news Release, go to http://multivu.prnewswire.com/mnr/baylorhealth/47429/
Many people think being on hospice means lying in a bed, barely conscious. However, this perception is not an accurate one. Many hospice patients' final moments are spent enjoying quality time with family and friends and creating special moments and memories. This would not be possible without the help of hospice.
The mission of hospice is to provide specialized care for patients in the final weeks and months of life and their families. More simply, hospice care supports living one’s life to the fullest with dignity regardless of how much time remains.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced at the mHealth Summit that it is expanding the beta program for its Patient Instructions feature, which enables physicians who use Medscape Mobile to securely send education and instructions on thousands of conditions, procedures and drugs to their patients who use the WebMD app for iPhone, or access WebMD on a PC or other mobile device. The company also previewed a forthcoming version of its WebMD app that leverages the 2net™ Platform from Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated (NASDAQ: QCOM), to enable health-conscious consumers to access and manage wireless health data from a wide array of fitness, wellness and medical devices directly from the app.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60050-webmd-accelerates-consumer-provider-connectivity-personalized-mobile-app
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced its new WebMD Pain Coach™ for iPhone, a unique free mobile application for consumers and patients living with chronic pain. As the leader in mobile health, WebMD provides trusted health information anytime and anywhere with its mobile web and applications for consumers and physicians. The new WebMD Pain Coach™ app builds on WebMD’s market-leading mobile applications through a holistic approach that helps users create a balanced lifestyle.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57975-webmd-launches-unique-new-mobile-app-for-those-living-with-chronic-pain
